Nano-Niclosamide Has Potential to Treat COVID-19 by Angela Mohan on May 6, 2021 at 9:21 AM
Long-acting injectable therapy has potential to treat COVID-19. In a paper published in the journal
Nanoscale, researchers of the University s Centre of Excellence for Long-acting Therapeutics (CELT) demonstrate nanoparticle-based niclosamide as an antiviral candidate.
Researchers started screening of various compounds within weeks of the first lockdown. Niclosamide is just one of the drug compounds identified that shows efficacy against SARS-CoV-2.
CELT scientists used nanoprecipitation to form redispersible solid drug nanoparticle formulations of niclosamide that can be stored as solids, reconstituted with water and utilised as long acting injectables.
Repurposing an existing, cheap drug into long-acting injectable therapy to treat Covid-19
Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.
In a paper published in the journal
Nanoscale, researchers from the University s Centre of Excellence for Long-acting Therapeutics (CELT) demonstrate the nanoparticle formulation of niclosamide, a highly insoluble drug compound, as a scalable long-acting injectable antiviral candidate.
The team started repurposing and reformulating identified drug compounds with the potential for COVID-19 therapy candidates within weeks of the first lockdown. Niclosamide is just one of the drug compounds identified and has been shown to be highly effective against SARS-CoV-2 in a number of laboratory studies.
Researchers find potential route to COVID-19 therapy
ANI
06 May 2021, 03:27 GMT+10
Liverpool [UK], May 5 (ANI): Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.
In a paper published in the journal Nanoscale, researchers from the University s Centre of Excellence for Long-acting Therapeutics (CELT) demonstrate the nanoparticle formulation of niclosamide, a highly insoluble drug compound, as a scalable long-acting injectable antiviral candidate.
The team started repurposing and reformulating identified drug compounds with the potential for COVID-19 therapy candidates within weeks of the first lockdown. Niclosamide is just one of the drug compounds identified and has been shown to be highly effective against SARS-CoV-2 in a number of laboratory studies.